These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26174892)

  • 1. The role of isoagglutinins in intravenous immunoglobulin-related hemolysis.
    Bellac CL; Hottiger T; Jutzi MP; Bögli-Stuber K; Sänger M; Hanschmann KM; Keller-Stanislawski B; Funk MB
    Transfusion; 2015 Jul; 55 Suppl 2():S13-22. PubMed ID: 26174892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor screening reduces the isoagglutinin titer in immunoglobulin products.
    Siani B; Willimann K; Wymann S; Marques Antunes A; Widmer E
    Transfusion; 2015 Jul; 55 Suppl 2():S95-7. PubMed ID: 26174905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products.
    Romberg V; Hoefferer L; El Menyawi I
    Transfusion; 2015 Jul; 55 Suppl 2():S105-9. PubMed ID: 26174887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012.
    Berg R; Shebl A; Kimber MC; Abraham M; Schreiber GB
    Transfusion; 2015 Jul; 55 Suppl 2():S36-46. PubMed ID: 26174896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti-A/B immunoaffinity chromatography and to a lesser extent with anti-A donor screening.
    Mallick R; Hubsch A; Barnes DG
    Transfusion; 2018 Dec; 58(12):2752-2756. PubMed ID: 30284263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-A and anti-B titers in donor plasma, plasma pools, and immunoglobulin final products.
    McVey J; Baker D; Parti R; Berg R; Gudino M; Teschner W
    Transfusion; 2015 Jul; 55 Suppl 2():S98-104. PubMed ID: 25981342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.
    Gerber S; Gaida A; Spiegl N; Wymann S; Antunes AM; Menyawi IE; Zurbriggen B; Hubsch A; Imboden M
    BioDrugs; 2016 Oct; 30(5):441-451. PubMed ID: 27646589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-A and anti-B: what are they and where do they come from?
    Branch DR
    Transfusion; 2015 Jul; 55 Suppl 2():S74-9. PubMed ID: 26174901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports.
    Shebl A; Gabriel S; Van Dinther K; Hubsch A; Lawo JP; Hoefferer L; Welsh S
    Transfusion; 2020 Jun; 60(6):1278-1286. PubMed ID: 32410287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital-based cohort study.
    Wallenhorst C; Patel A; Shebl A; Hubsch A; Simon TL; Martinez C
    Transfusion; 2020 Jul; 60(7):1381-1390. PubMed ID: 32488887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products.
    Hoefferer L; Glauser I; Gaida A; Willimann K; Marques Antunes A; Siani B; Wymann S; Widmer E; El Menyawi I; Bolli R; Spycher M; Imboden M
    Transfusion; 2015 Jul; 55 Suppl 2():S117-21. PubMed ID: 26174889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemolytic events after the administration of lyophilized versus liquid immune globulin: an analysis of a single manufacturer's safety database.
    Berg R; Jacob D; Fuellenhals E
    Transfusion; 2015 Aug; 55(8):1847-54. PubMed ID: 25867204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specifications for anti-A and anti-B in intravenous immunoglobulin: history and rationale.
    Thorpe SJ
    Transfusion; 2015 Jul; 55 Suppl 2():S80-5. PubMed ID: 26174902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibility.
    Mielke O; Fontana S; Goranova-Marinova V; Shebl A; Spycher MO; Wymann S; Durn BL; Lawo JP; Hubsch A; Salama A
    Transfusion; 2017 Nov; 57(11):2629-2638. PubMed ID: 28840942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening.
    Siani B; Willimann K; Wymann S; Marques AA; Widmer E
    Biol Ther; 2014 Dec; 4(1-2):15-26. PubMed ID: 24841428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of isoagglutinins in immunoglobulins for intravenous application by flow cytometry.
    Bürzle M; Hubsch A; Spiegl N; Roten T; Marques A; Martig L; Shebl A; Stadler D
    Anal Biochem; 2020 Feb; 591():113534. PubMed ID: 31821802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoagglutinin-reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin-associated hemolysis.
    Cen SY; Branch DR
    Transfusion; 2020 Feb; 60(2):250-255. PubMed ID: 31837028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populations.
    Cuesta H; El Menyawi I; Hubsch A; Hoefferer L; Mielke O; Gabriel S; Shebl A
    Transfusion; 2022 Sep; 62(9):1894-1907. PubMed ID: 35916266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis.
    Pendergrast J; Armali C; Callum J; Cserti-Gazdewich C; Jiwajee A; Lieberman L; Lau W; Lin Y; Parmar N; Pavenski K; Riden LS; Shehata N; Willie-Ramharack K; Tomlinson G; Tong TN; Binnington B; Branch DR;
    Transfusion; 2021 Apr; 61(4):1053-1063. PubMed ID: 33433931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemolysis after treatment with intravenous immunoglobulin due to anti-A.
    Morgan S; Sorensen P; Vercellotti G; Zantek ND
    Transfus Med; 2011 Aug; 21(4):267-70. PubMed ID: 21605202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.